Brief: Nordic Nanovector, Legochem Biosciences to jointly develop ADCs targeting leukaemias
10/10/2016 06:00
Oct 10 (Reuters) - Nordic Nanovector ASA NANOV.OL :
* Says has entered into cooperation with Legochem Biosciences 141080.KQ , South Korea-based
biopharmaceutical company, to develop novel antibody-drug conjugates (ADCs) targeting leukaemias
* Says collaboration supports co's strategy to expand its pipeline of targeted therapies to
include CD37-targeting antibody products conjugated to anti-cancer compounds that are not
radionuclides
Source text for Eikon: ID:nObiW2NfLa
Further company coverage: NANOV.OL
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on LigaChem Biosciences
See all newsBrief: Ligachem Biosciences - Receives Milestone Payment For First Patient Dosing Of 'Lcb97' Licensed To Ono Pharmaceutical
Brief: Ligachem Biosciences To Issue 170 Billion Won Worth Of Convertible Bonds
Brief: Ligachem Biosciences - Issues 2.21 Million New Preferred Shares
Brief: Ligachem Biosciences To Divest 5 Billion Won Worth Of Own Shares
Brief: Ligachem Biosciences To Divest 17 Billion Won Worth Of Own Shares